Adverse effects of advanced glycation end products on embryonal development

被引:0
|
作者
Hao, Lin [1 ,3 ]
Noguchi, Soichi [1 ]
Kamada, Yasuhiko [1 ]
Sasaki, Aiko [1 ,3 ]
Matsuda, Miwa [1 ,3 ]
Shimizu, Keiko [1 ,3 ]
Hiramatsu, Yuji [1 ,3 ]
Nakatsuka, Mikiya [1 ,2 ]
机构
[1] Okayama Univ Hosp, Dept Obstet & Gynecol, Okayama 7008558, Japan
[2] Okayama Univ, Grad Sch Hlth Sci, Okayama 7008558, Japan
[3] Okayama Univ, Grad Sch Med Dent & Pharmaceut Sci, Dept Obstet & Gynecol, Okayama 7008558, Japan
关键词
advanced glycation end products; blastocyst; embryo; in vitro fertilization; N-acetyl-L-cysteine;
D O I
暂无
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We studied the effects of advanced glycation end products (AGEs), which are known to accumulate in patients with diabetes, autoimmune diseases, or those who smoke, on embryonal development. Pronuclear (PN) embryos were obtained by flushing the fallopian tubes of rats after superovulation and mating. The cleavage rate and blastocyst yield were evaluated at 24, 72, 96, and 120 h of culture. Glyoxal, an AGE-forming aldehyde, suppressed embryonal development at every stage from PN to blastocyst in a concentration-dependent manner. The cleavage rate of the embryo was also significantly decreased by treatment with glyoxal at concentrations of 1 mM or higher. The blastocyst yield was significantly decreased by treatment with glyoxal at concentrations of 0.5 mM or higher. N-acetyl-L-cysteine (L-NAC) at I mM significantly suppressed the glyoxal-induced embryonal toxicity. BSA-AGEs at 5 mu g/ml or higher concentration significantly reduced the cleavage rate and blastocyst yield compared to those for BSA-treated embryos. L-NAC at I mM significantly suppressed BSA-AGE-induced embryonal toxicity. Because AGEs are embryo-toxic, AGE contamination may influence the pregnancy rate of in vitro fertilization and embryo transfer. AGEs, which are increased in women under pathological conditions, may also be involved in their infertility.
引用
收藏
页码:93 / 99
页数:7
相关论文
共 50 条
  • [31] Advanced glycation end products - Sparking the development of diabetic vascular injury
    Goldin, Alison
    Beckman, Joshua A.
    Schmidt, Ann Marie
    Creager, Mark A.
    CIRCULATION, 2006, 114 (06) : 597 - 605
  • [32] Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development
    Du, Chenping
    Whiddett, Rani O.
    Buckle, Irina
    Chen, Chen
    Forbes, Josephine M.
    Fotheringham, Amelia K.
    CELLS, 2022, 11 (21)
  • [33] Role of advanced glycation end products and their receptors in development of diabetic neuropathy
    Wada, R
    Yagihashi, S
    MAILLARD REACTION: CHEMISTRY AT THE INTERFACE OF NUTRITION, AGING, AND DISEASE, 2005, 1043 : 598 - 604
  • [34] Advanced Glycation End Products:Receptors for Advanced Glycation End Products Axis in Coronary Stent Restenosis: A Prospective Study
    Pearce, Colin
    Islam, Naorin
    Bryce, Robyn
    McNair, Erick Donnell
    INTERNATIONAL JOURNAL OF ANGIOLOGY, 2018, 27 (04) : 213 - 222
  • [35] Effects of Advanced Glycation End Products on Differentiation and Function of Osteoblasts and Osteoclasts
    Park, So Young
    Choi, Kyoung Hee
    Jun, Ji Eun
    Chung, Ho Yeon
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2021, 36 (37)
  • [36] Nicousamide blocks the effects of advanced glycation end products on renal cells
    Li, Hongyan
    Zhang, Yi
    Wang, Hongbo
    Zheng, Xuguang
    Chen, Xiaoguang
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2012, 674 (2-3) : 455 - 459
  • [37] The effects of advanced glycation end-products on skin and potential anti-glycation strategies
    Wang, Lingyu
    Jiang, Yanfei
    Zhao, Chunyue
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (04)
  • [38] Hemodialysis techniques and advanced glycation end products
    Tessitore, N
    Lapolla, A
    Aricó, CN
    Gammaro, L
    Bernich, P
    Fedele, D
    ADVANCED GLYCATION END PRODUCTS IN NEPHROLOGY, 2001, 131 : 33 - 39
  • [39] Advanced glycation end products and insulin resistance
    Unoki, Hiroyuki
    Yamagishi, Sho-ichi
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (10) : 987 - 989
  • [40] Advanced glycation end-products: a review
    Singh, R
    Barden, A
    Mori, T
    Beilin, L
    DIABETOLOGIA, 2001, 44 (02) : 129 - 146